A ground-glass nodule is a hazy spot on a CT scan that is rarely an emergency. Many are not cancer; where one is an early lung cancer, it is usually slow-growing and highly treatable. Long-term evidence supports two safe paths: careful surveillance for many nodules — sometimes for years — and surgery, which is essentially curative when chosen at the right moment. The right path depends on the nodule’s size, density, and how it changes over time.
Where surgery is the right answer, Dr Lawrence Okiror is a high-volume robotic anatomic-resection surgeon at London Bridge Hospital and at Guy’s and St Thomas’, with particular fluency in segmentectomy — the precise lung-preserving operation most suited to ground-glass nodule removal — and access to the ION robotic bronchoscopy pathway at London Bridge Hospital.
Last reviewed: June 2026 · Dr Lawrence Okiror FRCS(CTh) FRCSEd(CTh) · GMC 6150382
A ground-glass nodule is not a yes-or-no answer. It sits on a spectrum that runs from harmless scarring and old inflammation, through pre-cancerous change, to an early adenocarcinoma that behaves quite unlike typical lung cancer.
Where any individual nodule sits on that spectrum is read from specific, measurable features — how dense it is, whether it contains a solid part, its size, and how it has changed against your earlier scans. Two nodules that look identical on a single image can sit at opposite ends of the spectrum once those features and your prior imaging are weighed together. Reading them correctly, and deciding whether to watch or to operate, is what the consultation is for. Request a consultation at London Bridge Hospital within 2–3 working days →
A ground-glass nodule is a small area of lung that looks slightly hazy on a CT scan, rather than the normal dark black of healthy air-filled lung. The name comes from frosted bathroom glass — you can still see through it, but the view is softened rather than transparent. The haze on the CT scan represents a small patch of lung where the air spaces contain something other than just air: fluid, inflammation, scarring, or, in some cases, a thin layer of slow-growing cells.
A ground-glass nodule sits on a spectrum. At one end, the haze is very faint, the cells are precursor changes that may never become anything, and the right thing to do is to leave it alone and watch. At the other end, the haze has begun to thicken into something more solid in one corner — this signals that an indolent process has started to behave more like a typical cancer, and the right thing to do is usually to remove it before it has the chance to spread. In between sits the broader category of ground-glass adenocarcinoma: a slow-growing form of lung cancer that behaves very differently from the lung cancers most people fear, and that is often curable with limited surgery.
The most useful thing to understand at this stage is that the appearance on the CT scan tells your doctor a great deal about what kind of nodule it is, and that the decision about what to do next is rarely urgent. There is almost always time to obtain a specialist opinion, to gather any previous imaging for comparison, and to think through the choices carefully.
Picture a sheet of frosted glass. A faint, even haze across one corner is the early end of the spectrum. Over time, the haze may stay exactly the same, may slowly thicken, or may develop a small clear spot of dense glass within it. That dense spot — on a CT scan, a new solid component — is the change that matters most.
The development of a solid component is the single most important trigger for surgery. Most other changes can be safely observed.
Two large bodies of evidence support two positions at the same time. They are not in tension — they describe different patients and different moments in the natural course of a ground-glass nodule. The clinical task is to recognise which truth applies to which patient.
Truth one
The Japanese JCOG0804/WJOG4507L study followed 314 patients undergoing sublobar resection for small peripheral ground-glass-dominant lung cancers up to 2 cm. At 10 years, both recurrence-free survival and overall survival were 98.5 to 98.6 percent. There was a single local recurrence across the entire cohort. This is one of the highest cure rates reported anywhere in cancer surgery.
The American CALGB 140503 study (New England Journal of Medicine 2023) and the broader Japanese JCOG0802 study (Lancet 2022) both confirmed that sublobar resection — including segmentectomy — is non-inferior to lobectomy for small peripheral lung cancers up to 2 cm. The implication for ground-glass nodules is significant: the operation does not need to be large, healthy lung does not need to be sacrificed, and recovery is faster.
When surgery is the right answer, modern thoracic surgery offers as good an outcome as oncology produces — provided the operation is precisely chosen and well executed.
Truth two
The Liu et al study (Radiology 2025) followed 684 patients with 1,003 ground-glass nodules for up to 19 years. Comparing patients who chose CT surveillance against those who had surgery, there was no significant difference in 10-year overall survival — 94.7 percent for the surveillance group versus 97.6 percent for the surgery group, a difference that did not reach statistical significance. The accompanying editorial by Dr Mark Hammer at Harvard Medical School concluded that “resection as the standard treatment for all ground-glass nodules likely represents overtreatment.”
This finding is reinforced by the Chest 2025 study (Li and colleagues) of 1,676 patients, which found that observation was non-inferior to surgery for ground-glass nodules up to 2 cm with minimal solid components, after propensity-score matching. A separate Chest 2025 paper (Kim et al) showed that 3.9 percent of ground-glass nodules stable for a full 10 years still went on to grow — a reminder that surveillance is a long-term commitment rather than a one-time reassurance.
For many ground-glass nodules, careful surveillance with planned scans achieves the same long-term outcome as surgery, without the operation. The trade-off is sound: scans every year or two, in exchange for avoiding an operation that, for that nodule, was never necessary.
Both truths apply to real patients. The decision in any individual case turns on four specific features of the nodule and the patient — explained in the next section.
The choice between surveillance and surgery is not made by guesswork. Four specific features of the nodule and the patient are weighed together. Each is answerable by your CT scan, by serial imaging where available, and by a structured clinical conversation.
Question 1 · Size
How Big Is the Nodule?Ground-glass nodules below 6 mm rarely require any intervention. Between 6 and 10 mm, surveillance with planned scans is almost always the right approach. Above 10 mm, surveillance is still often correct, but the threshold for considering surgery shifts — particularly if the nodule is in a position where it can be removed by limited resection, or if other features are concerning.
Size matters — but it is not the most important feature. A 14 mm pure ground-glass nodule may be safer than a 9 mm nodule with a 3 mm solid component within it.
Question 2 · Density
How Dense, and Is There a Solid Component?Density is often more important than size. A pure ground-glass nodule (entirely hazy, no solid centre) tends to behave very indolently. A part-solid nodule (a hazy halo with a denser core) carries a higher likelihood of being an invasive adenocarcinoma. The size of any solid component — not the size of the whole nodule — is what most strongly predicts behaviour.
A new solid component appearing within a previously pure ground-glass nodule is the single most important trigger for considering surgery.
Question 3 · Behaviour
Is It Changing Over Time?Behaviour over time is a more powerful indicator than any single snapshot. A nodule that has been demonstrably stable for several years on serial CT scans can usually be watched with confidence. A nodule that is enlarging, becoming denser, or developing a new solid component has declared itself — and that declaration is what tilts the decision towards surgery.
If you have any previous chest CT — for any reason — bring it to the consultation. Comparison against an earlier scan is often the single most useful piece of information.
Question 4 · Context
What About Your Wider Picture?Multiple ground-glass nodules in the same lung. A strong family history of lung cancer. Significant smoking history. Other lung disease that limits surveillance. Personal preference about uncertainty — some patients find indefinite surveillance harder than the prospect of a definitive operation. All of these features feed into the right decision for the individual patient.
The right answer is rarely the same for two different people, even with apparently similar nodules. Context tilts the balance.
Where the field is going: a 2026 study in the Journal of Thoracic and Cardiovascular Surgery from Renji Hospital, Shanghai, found that a nodule’s density measured against the surrounding lung — the “lung/max CT value” — predicted invasiveness more reliably than size alone in pure ground-glass nodules. The principle is sound: density-led, patient-specific assessment. The model was derived in Chinese cohorts and is not yet validated for routine UK practice, so the framework above — size, density, behaviour, context — remains the right one, with refinement likely over the next 5 to 10 years.
For most ground-glass nodules below 10 mm without a solid component, careful surveillance is the right answer. The schedule is calibrated to the slow tempo of these lesions: low-dose CT every 6 to 12 months for the first 1 to 2 years, then less frequently if the nodule remains stable. Each scan is compared against the previous one, ideally by the same radiologist or by a radiologist with access to all prior imaging.
An increase in size of more than 2 mm; an increase in density; the appearance of a new solid component within the haze; or any change in shape that suggests behavioural transition. Each of these is a reasonable trigger to re-discuss the plan.
Surveillance is a long-term commitment. Many ground-glass nodules need 5 to 10 years of follow-up. A small but real proportion (3.9% in published 10-year data) can grow even after a decade of stability. Patients who choose surveillance should plan for a long programme, not a single reassuring scan.
If the nodule changes in any of the ways above, the conversation re-opens. Surgery now becomes part of the discussion, rather than the only available option. The patient who has been on surveillance for years has the advantage of a long imaging history — making the surgical decision sharper and easier.
Honest disclosure on the trade-off: surveillance means living with a small known abnormality on your CT scans for years. Most patients adapt to this readily once they understand the long-term data. A minority find the persistent uncertainty more difficult than the prospect of a definitive operation, and choose surgery on those grounds — which is also a legitimate decision when the nodule features support it. The right answer respects both the evidence and the patient.
Surgery is generally recommended when a ground-glass nodule develops a new solid component, when it grows on serial imaging, when it sits in a position where it can be removed with limited loss of healthy lung, or when the wider clinical picture tilts the balance towards intervention. When surgery is the right answer, the goal is precise: remove the nodule with a clear margin, take as little healthy lung as possible, and recover quickly.
Where pre-operative tissue diagnosis is needed, the ION robotic bronchoscopy pathway at London Bridge Hospital — one of a small number of private ION pathways in the UK — allows accurate biopsy of small or peripheral nodules without surgical incision. A positive result can lead directly to robotic resection in the same anaesthetic.
For ground-glass nodules, the operation of choice is most often anatomic segmentectomy — the precise removal of one anatomical segment of a lung lobe, taking the nodule with a clear margin while preserving the rest of the lung. Performed robotically, through small incisions.
Hospital stay typically 2 to 4 days. Most patients are back to light activities within 2 weeks and to full exercise tolerance within 4 to 6 weeks. The smaller the resection, the faster the recovery — which is the underlying logic of choosing segmentectomy where it is anatomically possible.
Why segmentectomy fluency matters for ground-glass nodules
Segmentectomy is technically more demanding than lobectomy. The anatomy of the lung segments is variable, the planes between segments are not always obvious, and the operation requires confident identification of the segmental artery, vein, and bronchus before division. In practices that perform it infrequently, segmentectomy is sometimes converted to lobectomy intra-operatively when the anatomy proves more complex than expected. In high-volume practices, segmentectomy is performed reliably and confidently — which means a ground-glass nodule patient receives a smaller operation with a shorter recovery and better preservation of lung function.
Dr Okiror’s personal robotic segmentectomy rate is 22.7 percent of his robotic anatomic resections, closely tracking the Guy’s and St Thomas’ institutional rate. Across the wider Guy’s and St Thomas’ service, 88.9 percent of segmentectomies are performed robotically — one of the highest robotic segmentectomy rates in any UK thoracic centre.
For ground-glass nodules where lobectomy is the right operation — particularly when the nodule sits centrally, when there are multiple nodules in the same lobe, or when staging requires it — the operation is performed robotically through the same small incisions. Across all anatomic resections, Dr Okiror’s personal robotic-or-keyhole rate is above 80 percent.
Ground-glass nodule patients benefit most from a service that combines high-volume anatomic resection experience, fluency in segmentectomy, access to advanced diagnostic technology, and a robust multidisciplinary team for complex decisions. Dr Okiror’s practice is built around these elements.
153 anatomic resections per year — approximately 1.94% of UK national thoracic anatomic resection volume in a single surgeon. Career total above 1,000.
Above 80% of these are robotic or keyhole. The UK average for wedge (non-anatomic) resection is around 14% of cases; Dr Okiror’s personal wedge rate is 6%, reflecting a strong preference for precise anatomic operations.
Personal robotic segmentectomy rate 22.7% of robotic anatomic resections. The Guy’s and St Thomas’ service performs 216 segmentectomies per year, 88.9% robotic.
For ground-glass nodule patients, segmentectomy fluency is the most operationally relevant credential — it determines how often a small lung-preserving resection is achievable rather than being converted to a lobectomy.
One of the few private ION pathways in the UK — robotic-assisted navigational bronchoscopy at London Bridge Hospital.
Allows accurate biopsy of small, peripheral, or ground-glass nodules without surgical incision — and a combined biopsy-and-resection pathway under a single anaesthetic where indicated.
Every complex case is discussed at a weekly multidisciplinary meeting that includes thoracic surgery, oncology, respiratory medicine, radiology, and pathology — with the same team running both NHS and private cases at GSTT and London Bridge Hospital.
For emphysema-related decisions, the monthly emphysema MDT also incorporates a lung transplantation physician and surgeon from Harefield Hospital.
For the diagnostic side of the pathway, see the dedicated ION robotic bronchoscopy page and the combined biopsy and robotic surgery page.
Whether the recommendation is surveillance or surgery, three things are worth understanding clearly before agreeing to any plan. They are not questions about who is the better doctor — they are questions about your own nodule, the answers to which should be plain to anyone advising you.
Density — particularly the presence or absence of a solid component — is more predictive of behaviour than size alone. A clear answer to this question, with the actual figure, should be available from your CT report or from the radiologist’s review.
If you have any previous chest CT scans — for any reason — they should be obtained and formally compared. A nodule that has been stable for years is in a fundamentally different category from one with no prior imaging history. If no prior imaging exists, the first interval scan becomes the most informative single test you will have.
If surgery is on the table, the operation that matters most for ground-glass nodules is precise segmentectomy — not lobectomy, not wedge resection. The recommendation should come from a surgeon who performs segmentectomy regularly and confidently, because the choice of operation has a real impact on lung preservation and recovery.
A specialist appointment with Dr Okiror is typically available within 2–3 working days at London Bridge Hospital or The Lister Hospital Chelsea. Bring CT chest imaging (current and any prior, where available), and any opinion or recommendation already given.
Outpatient consultations and surveillance are available at London Bridge Hospital, The Lister Hospital Chelsea, and at HCA outpatient clinics in Canary Wharf and the City of London. Patients in other regions or internationally can be reviewed initially by virtual consultation with imaging shared in advance.
Where pre-operative tissue diagnosis is needed, ION robotic bronchoscopy is performed at London Bridge Hospital — one of the few private centres in the UK offering it. Where the pathway leads to surgery, the operation can take place at London Bridge Hospital or, for straightforward unilateral resection in well-selected patients, at The Lister Hospital Chelsea. The same operator and the same multidisciplinary team handle both NHS and private cases.
For complex cases — multiple nodules, prior thoracic surgery, significant comorbidity, or international travel logistics — surgery takes place at London Bridge Hospital, where the perioperative and inpatient capability matches the complexity of the patient.
Insurance and self-pay: Dr Okiror is recognised by all major UK private medical insurers including AXA, BUPA, WPA, Vitality, Cigna, and Aviva. Transparent estimates are provided by Jo Mitchelson before any commitment is made — 020 7952 2882 or pa@lungsurgeon.co.uk. International self-pay packages can be priced separately and include all hospital, surgical, anaesthetic, and inpatient costs in a single transparent estimate.
Specialist assessment of a ground-glass nodule is available privately at London Bridge Hospital and The Lister Hospital Chelsea, with consultations within 2–3 days and imaging review completed before the consultation. The same operator and the same multidisciplinary team handle both NHS and private cases.
On the NHS, ground-glass nodules are managed through the Guy’s and St Thomas’ thoracic service. NHS waiting times to specialist clinic are typically several weeks; private waiting times are typically 2–3 days. All options — NHS and private — are discussed openly at every consultation.
Refer for assessment — let the multidisciplinary team determine the right balance between surveillance and intervention. Consider specialist surgical opinion for any of the following:
A brief referral letter with current CT chest and any prior imaging for size and density comparison is sufficient. Private assessments within 2–3 working days.
Contact Jo Mitchelson: 020 7952 2882 — pa@lungsurgeon.co.uk
AI-assisted referral letter generator: For GPs page →
Common questions from patients with a newly-discovered ground-glass nodule, from those weighing surveillance against surgery, and from referring clinicians.
Book a Consultation →Or call Jo Mitchelson:
020 7952 2882
Private appointments at London Bridge Hospital or The Lister Hospital Chelsea within 2–3 working days. Dr Okiror reviews investigations personally and advises honestly between surveillance and surgery, with no preference for either except what the evidence and the individual nodule support.
Jo Mitchelson, PA · 020 7952 2882 · pa@lungsurgeon.co.uk
St Thomas’ #1 UK · Guy’s #2 UK · London Bridge Hospital #10 UK · Newsweek World’s Best Hospitals 2026
Independent review for patients told they need urgent surgery, or who want a different perspective on a recommendation
ION Robotic BronchoscopyOne of the few private ION pathways in the UK — accurate biopsy of small and peripheral nodules without surgical incision
Combined Biopsy & Robotic SurgeryDiagnosis and resection in a single anaesthetic via the ION pathway
Robotic Lung SurgeryRobotic anatomic resection — segmentectomy, lobectomy, and the wider technique base
Lung Cancer Surgery in 2026The full clinical guide — diagnosis, staging, robotic surgery and the modern evidence base
AI in the Lung Cancer PathwayHow AI risk-scoring, ION robotic bronchoscopy and robotic resection now connect from scan to surgery
What Is a Lung Nodule?The wider picture — what a lung nodule is, how nodules are categorised, and what a ground-glass nodule is within that
A Shadow on Your ScanWhat it means to be told there is a shadow or spot on a chest scan, and the calm first steps that follow
Lung Cancer in Never-SmokersGround-glass adenocarcinoma is the pattern most often seen in those who have never smoked — what that means
Found on a Screening ScanMany ground-glass nodules are picked up incidentally or on screening — what to do when one is found this way